Physician profile
James Lasker
NPI 1215956289
$4,011.61
in general payments reported to CMS, 2019-2025
50 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $289 · 2020: $297 · 2021: $1,126 · 2022: $1,471 · 2023: $644 · 2024: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $644 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $644.17 |
| Education | $184.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $772.32 | 2021-2023 | Myrisk |
| Octapharma USA, INC. | $230.24 | 2020-2021 | |
| Astellas Pharma US INC | $225.70 | 2020-2024 | |
| E.R. Squibb & Sons, L.L.C. | $195.02 | 2020-2022 | |
| Daiichi Sankyo INC. | $190.39 | 2021-2023 | Enhertu |
| Pharmacyclics LLC, An Abbvie Company | $186.27 | 2021-2022 | |
| Janssen Biotech, INC. | $169.35 | 2019-2022 | |
| Eisai INC. | $130.52 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $125.55 | 2019-2022 | |
| Secura Bio, INC. | $123.98 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $113.25 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $110.40 | 2019-2022 | |
| Amgen INC. | $104.96 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $97.92 | 2019-2021 | |
| Glaxosmithkline, LLC. | $94.88 | 2020-2021 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lasker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.